News from DNAtrix A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

11 May, 2017, 09:00 ET DNAtrix Oncolytic Myxoma Virus Eliminates Treatment-Resistant Cancer

DNAtrix, a clinical stage biotechnology company developing oncolytic viruses for cancer, today announced a podium presentation on the use of...


24 Apr, 2017, 09:00 ET Precision Intratumoral Delivery of DNX-2401 with the Alcyone MEMS Cannula

DNAtrix, a clinical stage biotechnology company developing virus-based immunotherapies for cancer, and Alcyone Lifesciences, a leader in neural...


17 Nov, 2016, 16:00 ET DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that two presentations updating...


08 Nov, 2016, 16:00 ET DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced it has entered into an exclusive...


01 Nov, 2016, 16:00 ET DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the first patients have been...


04 Aug, 2016, 08:00 ET DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401

 DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced the award of a $2 million...


27 Jul, 2016, 12:40 ET DNAtrix Receives European Medicines Agency PRIME Designation

 DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the European Medicines...


21 Jul, 2016, 09:00 ET DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone's MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma

DNAtrix, a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer, announced the successful intratumoral...


09 Feb, 2016, 09:00 ET DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation for Treating Malignant Brain Tumors

 DNAtrix, a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer, announced that its lead product,...